1 |
ClinicalTrials.gov (NCT01353222) DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma. U.S. National Institutes of Health.
|
2 |
Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007 Aug 20;25(24):3680-7.
|
3 |
Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
|
4 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
|
5 |
Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
|
6 |
Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
|
7 |
2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
|
8 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
|
9 |
Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
|
10 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
|
11 |
Clinical pipeline report, company report or official report of Roche (2009).
|
12 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
|
|
|
|
|
|
|